Summary of Study ST001796
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001139. The data can be accessed directly via it's Project DOI: 10.21228/M8GH59 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST001796 |
Study Title | Changes in mesenteric lymph lipid profile of mice upon high-fat diet with and without Celecoxib |
Study Type | Untargeted lipidomics analysis |
Study Summary | Untargeted lipid profiling of mesenteric mice lymph from mice fed with CHOW, HFD and HFD supplemented with COx-2 inhibitor drug Celecoxib. It is proposed that Celecoxib can protect from deleterious morphological changes in lymphatic system caused by obesity due to HFD. |
Institute | Monash Institute of Pharmaceutical Sciences |
Department | Drug Delivery, Disposition and Dynamics |
Laboratory | Trevaskis Lab, Creek Lab |
Last Name | Anderson |
First Name | Dovile |
Address | 6 Anderson |
dovile.anderson@gmail.com | |
Phone | 8671141 |
Submit Date | 2021-05-17 |
Num Groups | 4 |
Total Subjects | 20 |
Num Males | 20 |
Publications | Manuscript NATMETAB-A20022406A Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential novel treatment target in obesity |
Raw Data Available | Yes |
Raw Data File Type(s) | raw(Thermo) |
Analysis Type Detail | LC-MS |
Release Date | 2021-06-02 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Treatment:
Treatment ID: | TR001886 |
Treatment Summary: | Celecoxib was incorporated into HFD feed at a dose equivalent to ~29 mg/kg/day (based on average food intake). Mice were fed for 15 weeks CFD diet (one group) and HFD diet (three groups). After 15 weeks two of the HFD groups were switched on HFD diet supplemented with Celecoxib and Celecoxib prodrug while other two groups continued unchanged CFD and HFD diets. Analysis at 22-34 weeks. |